News & Content

Xaira Therapeutics Announces the Appointment of Dr. Ian McCaffery as SVP, Translational Science and Early Clinical Development, and the Promotions of Dr. Ci Chu to Chief Discovery Officer and Dr. Bo Wang to Chief AI Scientist

Progressable Binders: The Binders that Matter

Up and down the ladder: The latest comings and goings

Xaira Therapeutics Announces the Appointment of Rachel Lane, Ph.D., as Senior Vice President, Business Development and Operations

Xaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology

Xaira Therapeutics raised nearly $1 billion. Here's its next act

X-Cell: Scaling Causal Perturbation Prediction Across Diverse Cellular Contexts via Diffusion Language Models

Announcing X-Cell, our virtual cell model trained on billions of genomic data points.

Xaira Therapeutics Launches X-Cell, Its First Virtual Cell Model, Trained on the Largest-Ever Genome-Wide Perturbation Dataset, X-Atlas/Pisces

How AI is Driving Drug Discovery: Xaira Therapeutics' Marc Tessier Lavigne

Reinventing drug discovery with AI

Virtual Cells: Four Paths To A Digital Revolution In Drug Discovery

Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer

What David Baker’s AI biotech unicorn Xaira has been up to

Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell

X-Atlas/Orion: Xaira Therapeutics Unveils Largest Publicly Available Genome-Wide Perturb-seq Dataset to Power Next-Generation AI for Biology

X-Atlas/Orion: Genome-wide Perturb-seq Datasets via a Scalable Fix-Cryopreserve Platform for Training Dose-Dependent Biological Foundation Models

AI Academic To Take His Work to ‘the Next Level’

Xaira Therapeutics Announces the Appointment of Bo Wang as SVP and Head of Biomedical AI

How scGPT pioneer Bo Wang, Ph.D. and Xaira’s $1B+ war chest aim to build a ‘virtual cell’

Xaira Therapeutics Announces the Appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as Chief Technology Officer

AI enters a new phase, and the Fortune 50 AI Innovators list identifies the companies leading it

Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer

Endpoints 11 winner Xaira Therapeutics: Biotech’s largest AI bet with A-list backers

Designed endocytosis-inducing proteins degrade targets and amplify signals

LinkedIn Top Startups 2024: The 50 U.S. companies on the rise

Inside the Seattle labs of Xaira, the AI-powered startup launched with $1B from investors

Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Why VC legend Bob Nelsen is making the biggest initial bet of his 37-year career on Xaira

Press Release: Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development

Atomically accurate de novo design of single-domain antibodies

Single cell sequencing as a general variant interpretation assay

De novo design of protein structure and function with RFdiffusion

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D